Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dolphin Medical ServicesBOM:526504 36 PS Ratio is 16.75 as of Jul. 16, 2026, which is 169% above its 10-year median of 6.22. GuruFocus rates BOM:526504 with a GF Score™ of 36/100 and a GF Value™ of ₹2.39 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Dolphin Medical Services ranks worse than 89.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Dolphin Medical Services's share price is ₹8.24.
Dolphin Medical Services's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.49. Hence, Dolphin Medical Services's PS Ratio for today is 16.75.
Warning Sign:
Dolphin Medical Services Ltd stock PS Ratio (=17.44) is close to 5-year high of 18.54.
The historical rank and industry rank for Dolphin Medical Services's PS Ratio or its related term are showing as below:
BOM:526504'
s PS Ratio Range Over the Past 10 Years
Min: 1.89 Med: 6.22 Max: 50.91
Current: 16.75
During the past 13 years, Dolphin Medical Services's highest PS Ratio was 50.91. The lowest was 1.89. And the median was 6.22.
BOM:526504's PS Ratio is ranked worse than 89.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.735
vs BOM:526504: 16.75
During the past 12 months, the average Revenue per Share Growth Rate of Dolphin Medical Services was 7.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.00% per year.
During the past 13 years, Dolphin Medical Services's highest 3-Year average Revenue per Share Growth Rate was 105.10% per year. The lowest was -54.10% per year. And the median was -6.05% per year.
Back to Basics: PS Ratio
Dolphin Medical Services (BOM:526504) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Dolphin Medical Services's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's PS Ratio distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Dolphin Medical Services's Share Price of today is ₹8.24. Dolphin Medical Services's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Dolphin Medical Services (BOM:526504) has a PS Ratio of 16.75 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Dolphin Medical Services and its competitors. This is 169% above median its historical median of 6.22. Over the past decade, Dolphin Medical Services' PS Ratio has ranged from 1.89 to 50.91. According to the industry distribution chart, Dolphin Medical Services ranks #179 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 89.5%.
Is Dolphin Medical Services' PS Ratio too high?
Dolphin Medical Services' current PS Ratio of 16.75 is 169% above median its 10-year median of 6.22. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 50.91. The Medical Diagnostics & Research industry median PS Ratio is 2.74. Dolphin Medical Services' value of 16.75 is 512.4% above this industry median. Based on the distribution chart, Dolphin Medical Services ranks #179 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #179 out of 200 companies for PS Ratio. This places Dolphin Medical Services in the lower half of its industry. The industry median PS Ratio is 2.74. Dolphin Medical Services' value of 16.75 is 512.4% above this benchmark. Historically, Dolphin Medical Services' own PS Ratio has ranged from 1.89 to 50.91 over the past decade. While the company's 10-year median is 6.22 vs. the industry median of 2.74, Dolphin Medical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.74, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dolphin Medical Services's current PS Ratio of 16.75 is 512.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Dolphin Medical Services and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dolphin Medical Services's current PS Ratio is 16.75, which is 169% above median its own 10-year median of 6.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.39, compared to a current price of ₹8.24 — trading 244.8% above its estimated fair value. The current PS Ratio is 16.75, which is 169% above median its 10-year median of 6.22 and 512.4% above the Medical Diagnostics & Research industry median of 2.74. Dolphin Medical Services' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current PS Ratio is 16.75 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹8.24 is trading 244.8% above its estimated GF Value™ of ₹2.39.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
PS Ratio: 16.75 (169% above median its 10-year median of 6.22)
GF Value™: ₹2.39 vs. price of ₹8.24 (244.8% above fair value)
Industry Position: 512.4% above the Medical Diagnostics & Research median (#179 of 200)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score
Get the complete analysis for BOM:526504
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
